Posts by: Marta Figueiredo

Marta Figueiredo

Marta Figueiredo holds a BSc in Biology and a MSc in Evolutionary and Developmental Biology from the University of Lisbon, Portugal. She is currently finishing her PhD in Biomedical Sciences at the University of Lisbon, where she focused her research on the role of several signalling pathways in thymus and parathyroid glands embryonic development.

February 15, 2021February 15, 2021

Darzalex Combos Linked to Stronger Cancer Eradication, Prolonged Survival

News

Adding Darzalex (daratumumab) to standard regimens for adults with relapsed or refractory multiple myeloma resulted in higher rates of deep and durable responses, according to exploratory analyses of two Phase ... Read more

February 8, 2021February 8, 2021

Under-the-skin Velcade Found to Work Better in Farydak Triple Combo

News

Using an under-the-skin formulation of Velcade (bortezomib), in combination with Farydak (panobinostat) and oral dexamethasone, leads to a better safety profile in people with relapsed or refractory (resistant) multiple myeloma ... Read more

February 1, 2021February 1, 2021

EU Committee Supports Nexpovio for Heavily Treated Myeloma Patients

News

A combination of Nexpovio (selinexor) and the corticosteroid dexamethasone has been recommended for conditional approval in the European Union to treat adults with relapsed or refractory multiple myeloma who received at ... Read more

January 8, 2021January 8, 2021

FDA Approval Sought for Cilta-cel CAR T-cell Therapy

News

Janssen and Legend Biotech are seeking U.S. approval for their investigational CAR T-cell therapy ciltacabtagene autoleucel — known as cilta-cel — to treat adults with relapsed or refractory (hard-to-treat) multiple ... Read more

December 14, 2020December 14, 2020

MMRF Joins Dana-Farber to Advance Research in Smoldering Myeloma

News

The Multiple Myeloma Research Foundation (MMRF) has joined forces with the Dana Farber Cancer Institute to develop new biomarkers and treatments for people with smoldering multiple myeloma (SMM) — a precursor condition to multiple myeloma. ... Read more

October 30, 2020October 30, 2020

CLR 131 Elicits Promising Response Rates in Triple-refractory Multiple Myeloma Trial

News

CLR 131, Cellectar Biosciences’ lead experimental candidate, resulted in a 40% response rate among people with multiple myeloma who failed to respond to three treatment modalities, according to additional data ... Read more

October 26, 2020October 26, 2020

Darzalex Delays Disease Progression After ASCT, Phase 3 Trial Reports

News

First-line maintenance therapy with Darzalex (daratumumab) significantly delays disease progression or death in adults with multiple myeloma who responded to autologous stem cell transplant (ASCT), according to data from the CASSIOPEIA trial’s second part. These findings, ... Read more

September 25, 2020September 25, 2020

Ninlaro Combo Fails to Halt Progression of Newly Diagnosed Multiple Myeloma, Trial Data Show

News

Adding Takeda’s Ninlaro (ixazomib) to Revlimid (lenalidomide) and dexamethasone failed to significantly extend life without disease progression in people newly diagnosed with multiple myeloma who are ineligible for autologous stem ... Read more

September 1, 2020September 1, 2020

Cilta-cel, CAR T-cell Treatment, Named Breakthrough Therapy in China

News

Legend Biotech and Janssen’s investigational CAR T-cell therapy ciltacabtagene autoleucel (cilta-cel) has been given breakthrough therapy designation in China as a potential treatment of relapsed or refractory multiple myeloma. Cilta-cel ... Read more

August 24, 2020August 24, 2020

FDA Approves Darzalex Triple Combo for Advanced Multiple Myeloma

News

The U.S. Food and Drug Administration (FDA) has approved Darzalex (daratumumab), in combination with Kyprolis (carfilzomib) and dexamethasone, to treat adults with relapsed or refractory multiple myeloma after one to three lines of therapy. Specifically, Darzalex — ... Read more